|
Originally published In Press as doi:10.1074/jbc.M003366200 on July 18, 2000
J. Biol. Chem., Vol. 275, Issue 39, 30701-30706, September 29, 2000
A Primitive ATP Receptor from the Little Skate Raja
erinacea*
Jonathan A.
Dranoff §¶,
Allison F.
O'Neill §,
Ann
Marie
Franco ,
Shi-Ying
Cai ,
Gregory C.
Connolly§ ,
Nazzareno
Ballatori§ ,
James L.
Boyer §, and
Michael H.
Nathanson §
From the Department of Medicine and Liver Study Unit,
Yale University School of Medicine, New Haven, Connecticut 06520, the § Mount Desert Island Biological Laboratories, Salisbury
Cove, Maine 04672, and the Department of Environmental
Medicine, University of Rochester School of Medicine,
Rochester, New York 14642
Received for publication, April 19, 2000, and in revised form, June 14, 2000
 |
ABSTRACT |
P2Y ATP receptors are widely expressed in
mammalian tissues and regulate a broad range of activities. Multiple
subtypes of P2Y receptors have been identified and are distinguished
both on a molecular basis and by pharmacologic substrate preference. Functional evidence suggests that hepatocytes from the little skate
Raja erinacea express a primitive P2Y ATP receptor lacking pharmacologic selectivity, so we cloned and characterized this receptor. Skate hepatocyte cDNA was amplified with degenerate oligonucleotide probes designed to identify known P2Y subtypes. A
single polymerase chain reaction product was found and used to
screen a skate liver cDNA library. A 2314-base pair cDNA clone was generated that contained a 1074-base pair open reading frame encoding a 357-amino acid gene product with 61-64% similarity to
P2Y1 receptors and 21-37% similarity to other P2Y
receptor subtypes. Pharmacology of the putative P2Y receptor was
examined using the Xenopus oocyte expression system and
revealed activation by a range of nucleotides. The receptor was
expressed widely in skate tissue and was expressed to a similar extent
in other primitive organisms. Phylogenetic analysis suggested that this
receptor is closely related to a common ancestor of the P2Y subtypes
found in mammals, avians, and amphibians. Thus, the skate liver P2Y receptor functions as a primitive P2Y ATP receptor with broad pharmacologic selectivity and is related to the evolutionary forerunner of P2Y1 receptors of higher organisms. This novel receptor
should provide an effective comparative model for P2Y receptor
pharmacology and may improve our understanding of nucleotide
specificity among the family of P2Y ATP receptors.
 |
INTRODUCTION |
Receptors for extracellular ATP mediate a variety of processes in
cells, including platelet aggregation, neurotransmission, vasomotor
responses, cell volume regulation, and epithelial secretion (1-8). P2Y
ATP receptors are seven transmembrane-spanning G protein-coupled receptors linked to inositol 1,4,5-trisphosphate-mediated
increases in [Ca2+]i (9). Multiple P2Y
receptor subtypes have been cloned (10-19) and share approximately
30% identity between classes, with few motifs conserved among these.
P2Y receptor subtypes are differentiated not only on a molecular level
but also by nucleotide specificity (20). Indeed, pharmacologic
selectivity provides an alternative means to identify P2Y receptor
subtypes (21-23).
Hepatocytes from the little skate Raja erinacea are
primitive polarized secretory epithelia (24). Like mammalian
hepatocytes (25), skate hepatocytes express P2Y receptors that link to
Ca2+ signaling and secretion (26, 27). However, skate
hepatocytes respond to a variety of nucleotide stimuli (26), so we
identified the P2Y receptor expressed by these cells.
 |
EXPERIMENTAL PROCEDURES |
Animals and Materials--
Male skates (R. erinacea,
0.7-1.2 kg), female sea urchins (Strongylocentrotus
droebachiensis), female blue crabs (Callinectes sapidus), male dogfish sharks (Squalus acanthias), and
male flounders (Pseudopleuronectes americanus) were caught
by net in Frenchmen's Bay, Maine, during the summers of 1998 and 1999. Marine organisms were maintained in large tanks with flowing 15 °C
seawater at Mount Desert Island Biological Laboratory (Salisbury
Cove, ME) for up to 4 days before use. ATP, ADP,
ATP S,1 UTP, and UDP were
purchased from Sigma. 2-Methylthioadenosine triphosphate
(2MeSATP) was purchased from Research Biochemical (Natick, MA). Fluo-3
was purchased from Molecular Probes (Pitchford, OR). All other
chemicals were of the highest quality commercially available.
Degenerate Oligonucleotide RT-PCR--
Skate liver was freshly
excised under RNase-free conditions, minced, and homogenized. Total RNA
was prepared using an organic-chaotropic reagent (RNAwiz; Ambion,
Austin, TX) and then treated with RQ1 DNase (Promega, Madison, WI) at
37 °C for 15 min, extracted in phenol/chloroform/isoamyl alcohol
(25:24:1), serially precipitated in isopropanol and 70% ethanol (v/v),
and redissolved in diethylpyrocarbonate-containing water. cDNA was
prepared from total RNA using Moloney murine leukemia virus
reverse transcriptase and dT18 primers (Advantage cDNA
Polymerase; CLONTECH, Palo Alto, CA). Degenerate
oligonucleotides designed to amplify conserved sequences within
transmembrane domains 3 and 7 in the P2Y subtypes
P2Y1 and P2Y2
(5'-CTCAC(C/G)TGCAT(A/C)AGCGTGCA-3' and
5'-(C/G)T(C/G)T(G/C)CCC(T/G)GCCAGGAAGTA-3' (28);
5'-AGCATCCT(C/G)TTCCTCAC(C/G)TG3' and
5'-GAG(G/T/C)A(T/C)(C/G)GGGTC(G/A)A(C/G)(A/G)CA(G/A)CTGTT-3' (10)) were used for cDNA PCR under the following conditions: 94 °C for 1 min; 30 cycles of 94 °C for 30 s, 58 °C for 1 min, and 72 °C for 1 min; and 72 °C for 5 min (Advantage cDNA
Polymerase; CLONTECH). Products were analyzed by
gel electrophoresis and purified (Qiagen, Valencia, CA).
Molecular Cloning and Sequence Analysis--
A custom skate
liver bacteriophage library was prepared (Stratagene, La Jolla,
CA). Plaques were titered, plated, and lifted onto charged nylon
membranes. A 32P-labeled probe was prepared from the
sequenced PCR product using random labeling at room temperature for
4 h (Roche Molecular Biochemicals). Membranes were screened with
the radiolabeled probe and washed according to manufacturer
instructions (Quik-Hyb; Stratagene). One positive clone was identified
from 1,200,000 plaques. The clone was excised, dissolved in chloroform,
and replated for secondary screening. Positive clones were identified
in secondary screening plates as described above and isolated using an
in vivo excision protocol. A positive clone was analyzed
using PCR and fully sequenced in both directions using an automated
sequencer by primer walking. Nucleotide and predicted amino acid
sequences were analyzed using Lasergene software (DNAStar, Madison,
WI), BLAST search (NCBI Protein Database), and Prosite. Phylogenetic
analysis was performed using the Clustal method (29).
Pharmacologic Characterization of the Cloned
Receptor--
Pharmacologic behavior of the putative receptor was
determined by expressing the cloned gene product in Xenopus
laevis oocytes (15, 30, 31). Capped skate liver P2Y cRNA was
prepared using T3 RNA polymerase according to the manufacturer's
instructions (MAXIscript; Ambion). Xenopus oocytes were
isolated and defolliculated in collagenase for approximately 90 min,
because only defolliculated oocytes lack endogenous P2Y receptors (32).
The oocytes were injected with putative skate liver P2Y cRNA or water
2-3 days before use and then injected with the
Ca2+-sensitive dye fluo-3 (1 mM; 40 nl/cell)
30-60 min before use. Oocytes were transferred to a specially designed
chamber then examined by time lapse confocal microscopy (30). Cells
were excited at 488 nm, and wavelengths of >515 nm were collected. A
Bio-Rad MRC 1024 or Olympus Fluoview confocal imaging system was used
to collect serial images as oocytes were perifused with ATP, 2MeSATP,
ADP, UTP, UDP, or ATP S. Responses to each nucleotide always were
compared with responses to ATP from the same group of oocytes, to
account for variability among different oocyte preparations.
Semi-quantitative Multiple Tissue RT-PCR--
cDNA PCR of
skate liver was performed under the following conditions: 94 °C for
5 min; 16-30 cycles of 94 °C for 30 s, 68 °C for 30 s,
and 72 °C for 1 min; and 72 °C for 5 min (Advantage cDNA
Polymerase; CLONTECH) with skate
P2Y-specific primers (5'-GAAGTCGCTGGGCAGGCTGAAGAA-3' and
5'-ACGTGGCGTAAACCCTTCGGTTCC-3'). PCR amplification was found to
be exponential for 16-22 cycles under these conditions. Negative control reactions were performed on RNA unexposed to reverse
transcriptase (RNA controls), water, HepG2 human hepatoblastoma cell
cDNA, and human brain cDNA. Total RNA was prepared from skate
liver, common bile duct, duodenum, rectal gland, gill, brain, heart,
and spleen, and then DNase treatment and cDNA synthesis were
performed as described above. Tissue cDNAs underwent PCR for 20 cycles, were electrophoresed on a 1.5% agarose gel, and were
transferred to a nylon membrane (Hybond; Amersham Pharmacia Biotech).
The membrane was prehybridized at 68 °C for 1 h, hybridized at
68 °C for 2 h with a radiolabeled probe prepared as described
under "Molecular Cloning and Sequence Analysis," and then washed
according to manufacturer instructions (QuikHyb; Stratagene). X-ray
films were placed atop the membrane at 80 °C for 24 h and
developed (33). A laser densitometer (Personal Densitometer SI;
Molecular Dynamics, Sunnydale, CA) was used to quantitate hybridization products.
Genomic DNA Dot Blots--
Genomic DNA was prepared from sea
urchin, blue crab, skate, dogfish shark, flounder, and frog according
to manufacturer's instructions (Qiagen). Genomic DNA from chicken,
rat, mouse, and human was purchased (CLONTECH).
Lyophilized aliquots of DNA (25 µg) were reconstituted in 3 µl of
water and then loaded onto a charged nylon membrane. The membrane was
prehybridized at 68 °C for 1 h, hybridized at 68 °C for
2 h with a radiolabeled probe prepared as described under
"Molecular Cloning and Sequence Analysis," and then washed
according to manufacturer instructions (QuikHyb; Stratagene).
Identically prepared membranes were hybridized to a radiolabeled human
glucose 3-phosphate dehydrogenase probe
(CLONTECH) under the same conditions. X-ray films
were placed atop the membrane at 80 °C for 24 h and
developed. A laser densitometer (Personal Densitometer SI; Molecular
Dynamics, Sunnydale, CA) was used to quantitate hybridization products.
 |
RESULTS |
Molecular Cloning of a Skate Liver P2Y Receptor--
To examine
whether homologues of cloned mammalian P2Y receptors could be
identified in skate liver, skate hepatocyte RNA was screened by RT-PCR
using two separate but overlapping degenerate oligonucleotide primers
designed to amplify sequences conserved among all known P2Y receptors
(10, 28). Only a single 500-600-base pair PCR product was identified
with either primer set, whereas no product was identified in water or
RNA controls (Fig. 1). Sequences of both
products contained an overlapping and identical segment and shared
50-60% identity to P2Y1 receptors of avians and mammals and 30-40% identity to other cloned P2Y receptors. The shorter PCR
product was used to screen a skate liver bacteriophage cDNA library
and produced a single hybridizing plaque. The plaque was excised,
analyzed by gel electrophoresis, and sequenced fully in both
directions. This clone (GenBankTM accession number
AF242850) was 2314 base pairs in length and contained a 1074-base pair
open reading frame, encoding a predicted protein sequence of 357 amino
acids (Fig. 2). Sequence analysis of this
clone revealed 61-64% identity to avian and mammalian P2Y1 receptors, 22-34% identity to avian and mammalian
P2Y2, P2Y4, P2Y6, and
P2Y11 receptors, and 37% identity to the frog
P2Y8 receptor at the amino acid level (Table
I). The deduced amino acid sequence contained seven predicted transmembrane helical domains, with an
extracellular N terminus and intracellular C-terminal tail. Other
motifs present included a G protein-coupled receptor signature motif,
four protein kinase C phosphorylation sites, two
cAMP-dependent protein kinase phosphorylation sites, four
casein kinase II phosphorylation sites, five N-glycosylation
sites, and four N-myristoylation sites. A computer-generated
phylogenetic analysis (DNAStar) suggested that the skate P2Y receptor
is most closely related to P2Y receptors of the P2Y1
subtype (Fig. 3A) and emerged
early in evolution from a common ancestor to P2Y1 receptors
of higher organisms (Fig. 3B).

View larger version (98K):
[in this window]
[in a new window]
|
Fig. 1.
Skate liver expresses a single P2Y
receptor. RT-PCR was used to probe skate liver RNA with two sets
of degenerate oligonucleotides designed to amplify regions conserved
among P2Y1, P2Y2, P2Y4, and
P2Y6. A single PCR product was amplified from skate liver
cDNA using either set of primers (lanes 1 and
2). No such product was obtained in RNA controls not exposed
to reverse transcriptase (lanes 3 and 4) or in
water controls (not shown).
|
|

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide and predicted amino acid sequences
of the skate liver P2Y receptor. The skate liver P2Y gene contains
2314 base pairs (A) with a 1074-base pair open reading frame
(bold type) and encodes a predicted 357 base pair amino acid
sequence (B) with seven predicted transmembrane helical
domains and a G protein-coupled receptor signature motif. The skate
liver P2Y amino acid sequence is shown aligned with human
P2Y1 and P2Y2. Residues indicated by
white letters on a black background are conserved
among all three sequences, and boxed letters indicate
residues conserved between any two sequences.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Percentage of nucleotide similarity between the putative skate liver
P2Y receptor and cloned P2Y subtypes
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Phylogenetic analysis of cloned P2Y
receptors. A computer-generated phylogenetic analysis of cloned
P2Y subtypes using the Clustal algorithm is shown in A. In
B, SLPY is shown as related to avian and mammalian
P2Y1 receptors. The skate liver P2Y receptor is closely
related to an early evolutionary ancestor of P2Y1 subtypes
of higher organisms.
|
|
Nucleotide Specificity of the Cloned Receptor--
To assess
whether this newly cloned gene product functioned as a P2Y receptor,
the product was expressed in Xenopus oocytes. The oocytes
then were injected with the Ca2+-sensitive dye fluo-3 and
then serially monitored using time lapse confocal microscopy to detect
nucleotide-induced increases [Ca2+]i.
Extracellular ATP (1 µM -100 µM) increased
[Ca2+]i in cRNA-injected but not water-injected
oocytes (Fig. 4). Increases in
[Ca2+]i also were seen in cRNA-injected oocytes
perifused with ATP in Ca2+-free medium. These findings
demonstrate that the putative skate liver P2Y receptor functions as a
P2Y ATP receptor.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
ATP increases cytosolic Ca2+ in
Xenopus oocytes expressing the skate liver P2Y
receptor. A, serial confocal images of an oocyte
expressing the cloned receptor. A Ca2+ wave crosses the
oocyte upon stimulation with 100 µM ATP. Result is
typical of n = 24 oocytes. B, graphical
representation of the increase in Ca2+ in the oocyte shown
in A detected at several different locations in the cell.
Differences between curves reflect the delay as the
[Ca2+]i wave crosses the oocyte. Similar
increases were seen in oocytes stimulated with ATP in
Ca2+-free media (n = 3), whereas no
increases were seen in water-injected oocytes (n = 7).
C, comparison of [Ca2+]i signaling in
an oocyte stimulated with 10 or 100 µM 2-MeSATP. A single
sustained [Ca2+]i wave is seen in the oocyte
stimulated with 100 µM 2-MeSATP (broken line),
whereas transient repetitive increases are seen in the oocyte
stimulated with 10 µM 2-MeSATP (solid
line).
|
|
To determine the nucleotide specificity of this receptor, oocytes also
were examined during perifusion with ADP, 2-MeSATP, UTP, UDP, and
ATP S. Perifusion with 100 µM concentrations of ATP,
ADP, 2-MeSATP, UTP, UDP, and ATP S each induced a single intense
[Ca2+]i wave that crossed the oocyte (Fig. 4,
A and B, and Table
II). Stimulation with lower
concentrations (1-10 µM) of ATP or 2-MeSATP induced
slower and less intense Ca2+ waves, some of which exhibited
oscillatory features (Fig. 4C). This
dose-dependent change in [Ca2+]i
signaling is typical in Xenopus oocytes expressing exogenous
G protein-coupled receptors (30). These findings thus demonstrate that,
unlike previously identified P2Y receptors, this P2Y receptor is
activated by a broad range of nucleotide ligands.
View this table:
[in this window]
[in a new window]
|
Table II
Broad nucleotide specificity of the cloned skate liver P2Y receptor
expressed in Xenopus oocytes
To account for variability among cRNA-injected oocytes,
nucleotide-induced Ca2+ increases were compared to ATP-induced
increases typical of those seen in Figure 4. Numbers in table reflect
the number of positive experiments/number of experiments attempted. A
variety of agonists, including ADP (P2Y1 agonist), 2-MeSATP
(P2Y1), UTP (P2Y2 and P2Y4), UDP
(P2Y6), and ATP S (nonhydrolyzable ATP analogue) induced
Ca2+ increases in Xenopus oocytes expressing the cloned skate
liver P2Y receptor, whereas adenosine and uridine did not.
|
|
Organ Distribution of the Skate Liver P2Y Receptor--
To
investigate the relative organ distribution of the skate liver P2Y
receptor, semi-quantitative multiple tissue RT-PCR was performed. This
technique was chosen because P2Y receptors frequently are found at
concentrations in which they can be detected by RT-PCR but not by
Northern blot (19). Skate P2Y receptor message was detected in all
tissues examined (liver, common bile duct, duodenum, rectal gland,
gill, brain, heart, spleen, and testis) but not in RNA controls, water
controls, HepG2 human hepatoblastoma cells, or human brain (Fig.
5A). Strongest expression was
seen in duodenum, spleen, rectal gland, brain, and liver (Fig.
5B), whereas expression in other organs was considerably
lower. This demonstrates that this P2Y receptor is not a liver-specific
gene but rather is expressed throughout in the skate to varying
degrees.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 5.
The cloned skate liver P2Y receptor is
expressed widely in skate. A, semi-quantitative RT-PCR
was used to probe RNA from a range of organs using oligonucleotide
primers specific to this receptor. 500-base pair PCR products were
amplified from cDNA from a range of organs, transferred to a nylon
membrane, and hybridized to a radionucleotide skate liver P2Y
probe. B, densitometry analysis of blot in A
reveals strong expression in liver (lane 1), duodenum
(lane 3), rectal gland (lane 4), brain
(lane 6), and spleen (lane 8), whereas weaker
expression was found in common bile duct (lane 2), gill
(lane 5), heart (lane 7), and testis (lane
9). No PCR products were seen in RNA controls not exposed to
reverse transcriptase or in water, rat hepatocyte cDNA, HepG2 human
hepatoblastoma cells, or human brain cDNA (not shown).
|
|
Phylogenetic Distribution of the Skate Liver P2Y Receptor--
To
assess whether other members of the animal kingdom express homologues
of the skate liver P2Y receptor, genomic DNAs of representative species
were examined by dot blot (Fig.
6A). Strong hybridization was
seen to crab, skate, shark, and flounder, whereas weak hybridization
was seen to other species (Fig. 6B). This suggests that
similar genes are expressed throughout the animal kingdom with more
closely related genes found in marine species.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
Skate liver P2Y receptor homologues are
expressed in a range of organisms. A, genomic DNA dot
blot. Genomic DNA from representative organisms in the animal kingdom
was hybridized to a radionucleotide skate liver P2Y probe under
high stringency conditions. A duplicate blot was hybridized
under identical conditions radionucleotide glucose 3-phosphate
dehydrogenase probe (not shown). B, densitometry
analysis of A. Skate liver P2Y densitometry was normalized
to glucose 3-phosphate dehydrogenase densitometry. Strongest
hybridization is seen to skate (3), shark (4),
flounder (5), and crab (2), whereas minimal
signals are seen in frog (6), sea urchin (1),
chicken (7), rat (8), mouse (9), and
human (8).
|
|
 |
DISCUSSION |
P2Y receptors are expressed widely in higher organisms. Humans and
rodents each express at least four P2Y receptor subtypes (8). Although
some tissues express only one or two P2Y subtypes at either the apical
or basolateral plasma membrane (1-3), others express multiple P2Y
subtypes, each of which may be expressed at either the apical,
basolateral, or both membrane domains (3, 21, 23, 34). This highlights
the complex organization of purinergic signaling in higher organisms.
In contrast to this complex expression of P2Y receptors in higher
organisms, the current findings suggest that the primitive chordate
R. erinacea expresses just a single P2Y receptor. The skate
liver P2Y receptor has likely evolved within the subfamily of
P2Y1 receptors yet is molecularly distinct from either
avian or mammalian P2Y1 subtypes. Because this receptor is
activated by a variety of diphosphate and triphosphate nucleotides, its pharmacologic specificity may be less developed than P2Y receptors of
higher organisms. Furthermore, other receptors that link to inositol
1,4,5-trisphosphate formation and [Ca2+]i
signaling are not detectable in skate liver (26), suggesting that
nucleotide receptors are among the most primitive extracellular
receptors expressed in the animal kingdom. Moreover, the skate liver
P2Y receptor is distributed throughout the skate, so purinergic
signaling may be controlled similarly in all skate tissues. Despite its
widespread tissue distribution and primitive pharmacology, this P2Y
receptor regulates bile secretion in liver (26). Thus, this simple
extracellular receptor is linked to specific physiologic responses.
The primitive nature of the skate liver P2Y receptor is highlighted by
the finding that it is related to similar molecules in even more
primitive organisms. Strong hybridization was seen with blue crab,
indicating that a P2Y receptor is likely expressed in this
invertebrate. Weak hybridization was seen with sea urchin, suggesting
that a P2Y receptor may be expressed in this primitive invertebrate as
well. Because the skate liver P2Y receptor is most closely related to
the P2Y1 subfamily, it is likely that the common ancestor
of P2Y receptors arose in a simpler invertebrate such as the sea urchin
rather than in an early chordate such as the skate. It has been
suggested that nucleotides may have arisen as signaling molecules early
in evolution because they were already plentiful as intracellular
energy sources (9). A related hypothesis is that the initial efflux of
nucleotides occurred as cells were injured or dying, and evolution of
early P2Y receptors allowed neighboring cells to become aware of cell
injury or death. Thus, in addition to being among the most primitive
signaling mechanisms, purinergic signaling may be among the oldest
signaling mechanisms.
What advantage could be conferred by the evolution of single P2Y
receptors with less selective pharmacology and widespread tissue
distribution to the complex expression of multiple P2Y receptors with
highly selective pharmacology and tissue distributions? One explanation
is that P2Y receptor subtypes evolved in higher organisms to allow
tissue-specific responses to release of particular nucleotides. The
recent finding that some P2Y receptors may have distinct signal
transduction mechanisms (18) suggests there may be even further fine
tuning of responses through cross-talk between second messenger
pathways. Further identification and characterization of P2Y receptors
from organisms that evolved after the skate but before mammals and
birds may help to address this important question.
 |
ACKNOWLEDGEMENTS |
We thank Joe Mindell and Saul Karpen for
helpful discussions and John Henson, David Towle, John Forrest, and
Larry Renfro for providing marine species for phylogenetic analysis.
 |
FOOTNOTES |
*
This work was supported by a Basic Science Award from the
Glaxo Institute of Digestive Health (to J. A. D.), a Student
Research Award from the American Digestive Health Foundation (to
A. F. O.), National Institutes of Health Grants DK45710,
DK34989, DK25636, and ES03828, and grants from the American Heart
Association, the Cystic Fibrosis Foundation, and the Salisbury Cove
Research Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Yale University
School of Medicine, Section of Digestive Diseases, LMP 1080, 333 Cedar
St., New Haven, CT 06510. Tel.: 203-932-5711 (ext. 3318); Fax:
203-785-7273; E-mail: jonathan.dranoff@yale.edu.
Published, JBC Papers in Press, July 18, 2000, DOI 10.1074/jbc.M003366200
 |
ABBREVIATIONS |
The abbreviations used are:
ATP S, adenosine
5-O-3-thiotriphosphate;
2MeSATP, 2-methylthioadenosine
triphosphate;
RT, reverse transcriptase;
PCR, polymerase chain
reaction.
 |
REFERENCES |
| 1.
|
Fabre, J. E.,
Nguyen, M.,
Latour, A.,
Keifer, J. A.,
Audoly, L. P.,
Coffman, T. M.,
and Koller, B. H.
(1999)
Nat. Med.
5,
1199-1202
|
| 2.
|
Leon, C.,
Hechler, B.,
Freund, M.,
Eckly, A.,
Vial, C.,
Ohlmann, P.,
Dierich, A.,
LeMeur, M.,
Cazenave, J. P.,
and Gachet, C.
(1999)
J. Clin. Invest.
104,
1731-1737
|
| 3.
|
Cressman, V. L.,
Lazarowski, E.,
Homolya, L.,
Boucher, R. C.,
Koller, B. H.,
and Grubb, B. R.
(1999)
J. Biol. Chem.
274,
26461-26468
|
| 4.
|
Wang, Y.,
Roman, R.,
Lidofsky, S. D.,
and Fitz, J. G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12020-12025
|
| 5.
|
Osipchuk, Y.,
and Cahalan, M.
(1992)
Nature
359,
241-244
|
| 6.
|
Paradiso, A. M.,
Mason, S. J.,
Lazarowski, E. R.,
and Boucher, R. C.
(1995)
Nature
377,
643-646
|
| 7.
|
Schwiebert, E. M.,
Egan, M. E.,
Hwang, T.,
Fulmer, S. B.,
Allen, S. S.,
Cutting, G. R.,
and Guggino, W. B.
(1995)
Cell
81,
1063-1073
|
| 8.
|
Ralevic, V.,
and Burnstock, G.
(1998)
Pharmacol. Rev.
50,
413-492
|
| 9.
|
Burnstock, G.
(1997)
Neuropharmacology
36,
1127-1139
|
| 10.
|
Tokuyama, Y.,
Hara, M.,
Jones, E. M. C.,
Fan, Z.,
and Bell, G. I.
(1995)
Biochem. Biophys. Res. Commun.
211,
211-218
|
| 11.
|
Boyer, J. L.,
Waldo, G. L.,
and Harden, T. K.
(1997)
Mol. Pharmacol.
52,
928-934
|
| 12.
|
Boyer, J. L.,
Lazarowski, E. R.,
Chen, X.-H.,
and Harden, T. K.
(1993)
J. Pharmacol. Exp. Ther.
267,
1140-1146
|
| 13.
|
Bogdanov, Y. D.,
Wildman, S. S.,
Clements, M. P.,
King, B. F.,
and Burnstock, G.
(1998)
Br. J. Pharmacol.
124,
428-430
|
| 14.
|
Webb, T. E.,
Henderson, D.,
King, B. F.,
Wang, S.,
Simon, J.,
Bateson, A. N.,
Burnstock, G.,
and Barnard, E. A.
(1996)
Mol. Pharmacol.
50,
258-265
|
| 15.
|
Webb, T. E.,
Simon, J.,
Krishek, B. J.,
Bateson, A. N.,
Smart, T. G.,
King, B. F.,
Burnstock, G.,
and Barnard, E. A.
(1993)
FEBS Lett.
324,
219-225
|
| 16.
|
Lustig, K. D.,
Shiau, A. K.,
Brake, A. J.,
and Julius, D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5113-5117
|
| 17.
|
Parr, C. E.,
Sullivan, D. M.,
Paradiso, A. M.,
Lazarowski, E. R.,
Burch, L. H.,
Olsen, J. C.,
Erb, L.,
Weisman, G. A.,
Boucher, R. C.,
and Turner, J. T.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3275-3279
|
| 18.
|
Communi, D.,
Govaerts, C.,
Parmentier, M.,
and Boeynaems, J. M.
(1997)
J. Biol. Chem.
272,
31969-31973
|
| 19.
|
Webb, T. E.,
Henderson, D. J.,
Roberts, J. A.,
and Barnard, E. A.
(1998)
J. Neurochem.
71,
1348-1357
|
| 20.
|
Nicholas, R. A.,
Lazarowski, E. R.,
Watt, W. C.,
Boyer, J.,
and Harden, T. K.
(1996)
J. Autonomic Pharmacol.
16,
319-323
|
| 21.
|
Hwang, T.-H.,
Schwiebert, E. M.,
and Guggino, W. B.
(1996)
Am. J. Physiol.
270,
C1611-C1623
|
| 22.
|
Lazarowski, E. R.,
Paradiso, A. M.,
Watt, W. C.,
Harden, T. K.,
and Boucher, R. C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2599-2603
|
| 23.
|
Luo, X.,
Zheng, W.,
Yan, M.,
Lee, M. G.,
and Muallem, S.
(1999)
Am. J. Physiol.
277,
C205-C215
|
| 24.
|
Smith, D. J.,
Grossbard, M.,
Gordon, E. R.,
and Boyer, J. L.
(1987)
J. Exp. Zool.
241,
291-296
|
| 25.
|
Boyer, J. L.,
and Nathanson, M. H.
(1999)
in
Schiff's Diseases of the Liver
(Schiffer, S. M.
, and Maddrey, W. C., eds)
, pp. 119-146, Lippincott-Raven, Philadelphia, PA
|
| 26.
|
Nathanson, M. H.,
and Mariwalla, K.
(1996)
Am. J. Physiol.
270,
R561-R570
|
| 27.
|
Nathanson, M. H.,
O'Neill, A. F.,
and Burgstahler, A. D.
(1999)
J. Exp. Biol.
202,
3049-3056
|
| 28.
|
Chen, Z.-P.,
Krull, N.,
Xu, S.,
Levy, A.,
and Lightman, S. L.
(1996)
Endocrinology
137,
1833-1840
|
| 29.
|
Higgins, D. G.,
and Sharp, P. M.
(1988)
Gene (Amst.)
73,
237-244
|
| 30.
|
Nathanson, M. H.,
Moyer, M. S.,
Burgstahler, A. D.,
O'Carroll, A. M.,
Brownstein, M. J.,
and Lolait, S. J.
(1992)
J. Biol. Chem.
267,
23282-23289
|
| 31.
|
King, B. F.,
Neary, J. T.,
Zhu, Q.,
Wang, S.,
Norenberg, M. D.,
and Burnstock, G.
(1996)
Neuroscience
74,
1187-1196
|
| 32.
|
Bogdanov, Y. D.,
Dale, L.,
King, B. F.,
Whittock, N.,
and Burnstock, G.
(1997)
J. Biol. Chem.
272,
12583-12590
|
| 33.
|
Zheng, H.,
Yan, W.,
Toppari, J.,
and Harkonen, P.
(2000)
BioTechniques
28,
832-834
|
| 34.
|
Christoffersen, B. C.,
Hug, M. J.,
and Novak, I.
(1998)
Pflügers Arch. Eur. J. Physiol.
436,
33-39
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Burnstock
Physiology and Pathophysiology of Purinergic Neurotransmission
Physiol Rev,
April 1, 2007;
87(2):
659 - 797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Y. Lee, S. C. Wolff, R. A. Nicholas, and S. M. O'Grady
P2Y Receptors Modulate Ion Channel Function through Interactions Involving The C-Terminal Domain
Mol. Pharmacol.,
April 1, 2003;
63(4):
878 - 885.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|